Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis

Prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) prevents Pneumocystis jirovecii pneumonia and nocardiosis in immunocompromised patients but sometimes is avoided because of purported allergies or side effects. Of 25 immunocompromised patients receiving alternative prophylaxis in whom nocardiosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Puing, Alfredo G., Epstein, David J., Banaei, Niaz, Subramanian, Aruna K., Liu, Anne Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462344/
https://www.ncbi.nlm.nih.gov/pubmed/34545802
http://dx.doi.org/10.3201/eid2710.210620
_version_ 1784572189315432448
author Puing, Alfredo G.
Epstein, David J.
Banaei, Niaz
Subramanian, Aruna K.
Liu, Anne Y.
author_facet Puing, Alfredo G.
Epstein, David J.
Banaei, Niaz
Subramanian, Aruna K.
Liu, Anne Y.
author_sort Puing, Alfredo G.
collection PubMed
description Prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) prevents Pneumocystis jirovecii pneumonia and nocardiosis in immunocompromised patients but sometimes is avoided because of purported allergies or side effects. Of 25 immunocompromised patients receiving alternative prophylaxis in whom nocardiosis developed, 16 subsequently tolerated TMP/SMX treatment. Clinicians should consider TMP/SMX allergy evaluation and rechallenging to assess patient tolerance.
format Online
Article
Text
id pubmed-8462344
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-84623442021-10-07 Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis Puing, Alfredo G. Epstein, David J. Banaei, Niaz Subramanian, Aruna K. Liu, Anne Y. Emerg Infect Dis Research Letter Prophylactic trimethoprim/sulfamethoxazole (TMP/SMX) prevents Pneumocystis jirovecii pneumonia and nocardiosis in immunocompromised patients but sometimes is avoided because of purported allergies or side effects. Of 25 immunocompromised patients receiving alternative prophylaxis in whom nocardiosis developed, 16 subsequently tolerated TMP/SMX treatment. Clinicians should consider TMP/SMX allergy evaluation and rechallenging to assess patient tolerance. Centers for Disease Control and Prevention 2021-10 /pmc/articles/PMC8462344/ /pubmed/34545802 http://dx.doi.org/10.3201/eid2710.210620 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research Letter
Puing, Alfredo G.
Epstein, David J.
Banaei, Niaz
Subramanian, Aruna K.
Liu, Anne Y.
Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis
title Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis
title_full Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis
title_fullStr Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis
title_full_unstemmed Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis
title_short Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis
title_sort nocardiosis in immunocompromised patients on alternative pneumocystis prophylaxis
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462344/
https://www.ncbi.nlm.nih.gov/pubmed/34545802
http://dx.doi.org/10.3201/eid2710.210620
work_keys_str_mv AT puingalfredog nocardiosisinimmunocompromisedpatientsonalternativepneumocystisprophylaxis
AT epsteindavidj nocardiosisinimmunocompromisedpatientsonalternativepneumocystisprophylaxis
AT banaeiniaz nocardiosisinimmunocompromisedpatientsonalternativepneumocystisprophylaxis
AT subramanianarunak nocardiosisinimmunocompromisedpatientsonalternativepneumocystisprophylaxis
AT liuanney nocardiosisinimmunocompromisedpatientsonalternativepneumocystisprophylaxis

Ejemplares similares